All In Biotech

BLA 021106 · Pharmacia

Somavert

Pegvisomant · Subcutaneous

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Mar 25, 2003

Approved uses

3

Original approval plus efficacy supplements

Registered trials

31

5 Phase 3, 1 recruiting

FAERS reports

4,106

2,291 serious, 320 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 18, 2025.

SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. SOMAVERT is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. ( 1 )

Mechanism: Pegvisomant selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of IGF-1, as well as other GH-responsive serum proteins such as free IGF-1, the acid-labile subunit of IGF-1 (ALS), and insulin-like growth factor binding protein-3 (IGFBP-3).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 27, 2023 Supplement 74 · Efficacy OrphanLetterLabel
  • Dec 10, 2013 Supplement 36 · Efficacy LetterLabel
  • Mar 25, 2003 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
5 products under this application
  • SOMAVERT · PEGVISOMANT 30MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
  • SOMAVERT · PEGVISOMANT 20MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
  • SOMAVERT · PEGVISOMANT 10MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
  • SOMAVERT · PEGVISOMANT 25MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
  • SOMAVERT · PEGVISOMANT 15MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegvisomant" as an intervention, any sponsor and status, largest first.

All 31 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use491
  • drug ineffective438
  • headache404
  • fatigue387
  • insulin-like growth factor increased380
  • arthralgia300
  • product dose omission issue268
  • injection site pain261
  • diarrhoea256
  • nausea231
  • pain213
  • blood pressure increased206

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200423
200535
200639
200722
200823
200938
201088
201173
2012102
2013156
2014164
2015176
2016181
2017276
2018382
2019402
2020354
2021245
2022350
2023455
2024261
2025196
202665

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Somavert (PEGvisomant)

2024 spending

$37.3M

Beneficiaries

257

2,381 claims

Per beneficiary

$145,112

$533.93 per unit

View as table
YearSpending
2020$36,050,937
2021$33,892,085
2022$35,283,015
2023$37,083,662
2024$37,293,740

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 94 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.